Novel Combination Therapy for Prostate Carcinoma

Abstract

We established for the first time that an oral DNA minigene vaccine encoding muring vascular endothelial growth factor receptor-2 (FLK-l)-derived nonapeptides with H-2Db anchor residues can evoke a CD8+ cytotoxic T-cell response. These CTLs effectively kill proliferating endothelial cells int eh neovasculature of RM-9 murine prosate carcinoma cells leading to the effective suppression of tumor growth and hepatic as well as pulmonary metastases in syngeneic C57BL/6J mice. These data strongly support the contention that the murine vascular endothelial growth factor receptor-2 (FLK-l), overexpressed on proliferating endothelial cells in the tumor vasculature, is an effective target for DNA-minigene vaccines against prostate cancer.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Feb 01, 2004
Accession Number
ADA423719

Entities

People

  • Rong Xiang

Organizations

  • Scripps Research

Tags

DTIC Thesaurus Topics

  • Biomedical Research
  • Cells
  • Coding
  • Combination Therapy
  • Endothelial Cells
  • Growth Factors
  • Immunization
  • Lymphocytes
  • Neoplasms
  • Production
  • Prostate
  • Prostate Cancer
  • Therapy
  • Vaccination
  • Vaccines

Fields of Study

  • Biology

Readers

  • Immunology
  • Oncology (Cancer Research).

Technology Areas

  • Biotechnology
  • Biotechnology - Cancer Biotech